The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
Francesco Passamonti
Consultant or Advisory Role - Novartis (U)
Guray Saydam
No relevant relationships to disclose
Liberata Lim
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (I)
Mahmudul H Khan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nadjat Mounedji
Employment or Leadership Position - Novartis
Martin Griesshammer
No relevant relationships to disclose